癌症患者生活质量评估量表QLQ252的设计及质量评价

QLQ252430030,:QLQ252:133,QLQ252:QLQ25252,6;QLQ252Pearson01334(P0101),019242,019404,94100%,0187,Pearson01574(P0101);:(P0105);:93166%,14130,12:QLQ252,;;;:R730159:B:1009-0460(2005)03-0235-05DevelopmentofqualityoflifequestionnaireforcancerpatientsQLQ252andtheevaluationofquestionnairepsqualityLIUFu2an,YUShi2ying.DeptofMedicalOncology,TheAffiliatedTongjiHospitalofHuazhongTechnologyUni2versity,Wuhan430030,ChinaAbstractObjective:Todevelopaself2assessedquestionnaireofqualityoflifeQLQ252suitableforthepeopleofChinesecul2turebackground.Methods:Wesurveyed133casesofcancerpatientstoevaluatethequalityofQLQ252byreliability,validity,respon2sivenessandfeasibilitytoreflectthequalityofthequestionnaire.Results:Thenewquestionnairecomposedof52entrieswasformedby6domainswhichwerephysical,psychological,independent,socialandenvironmentalrelations,spiritsupportandsatisfactorydegree.ThepatientspreliabilityPearsoncorrelationwas01334(P0101),split2halfreliabilitywas019242,Cronbachpscoefficientwas019404.Thecontentvaliditywas94100%,constructvalidityshowedthatpercentageofcumulativeis0187,ThePearsoncoefficientofcriterion2relatedvaliditywas01574(P0101).TheresponsivenesswasevaluatedbythedifferenceofQOLofpre/duringandposttreatmentwhichwassignificant(P0105).Thefeasibilitywasevaluatedbycompletedrate,averagecompletedtimeandthemediantimewhichwere93166%,1413minutes,and12minutes.Conclusion:Thereliability,validity,responsivenessandfeasibilityofQLQ252arepracticalinmedicalclinic.TheQLQ252maybeusedwidelybythemedicalclinicinChinatoevaluatetheQOLofcancerpatients.KeyWordsQOL;Cancer;Questionnaire;Evaluation,,(CR)(PR)(Qualityoflife,QOL)QOL,,,,QOL,QOL,,,,,,1,,,53220056103ChineseClinicalOncology,Jun.2005,Vol.10,No.311111111WHO,,10261111252Likert,,,;,11113()()4[1]112,,11311311,()()(),,,65213311312,,,,,,,114,,,115SPSS1110Pearson[2]2211102,75,,,,,,75,652,QLQ252212133133,16,10,10,33,39,25;46,8721352,2131152,KMO0172;Bartlettps,17,86180%171,123(),,46130%;45678,,18150%;9101112,,10170%;131415,,6197%;16,,2123%;17,,2109%60187,21312[3],,2063220056103ChineseClinicalOncology,Jun.2005,Vol.10,No.3,94100%117(%)1129129211011831618441416951411961314971312081//219391/2181101/2172111/2163121//2154131/2143141212915121251612123171210921313,PearsonPearson01574(P0101)214,,(),43,Pearson,01334(P0101),Pearsonr,R=2r/1+r018591,019242Cronbachpsalpha,0194042153,73220056103ChineseClinicalOncology,Jun.2005,Vol.10,No.3(€xS)1121203417096140261607414018110,,(P0105),216142,133,93166%;14130,12,[3]217,,,H2015,52,3(QOL),30,,,:,5060QOL,40KPSQOL,70,,QOL80,80,,,,QOL,,,QOL,,,QOL,,,QOL[4]QOLHRQOL,,,QOL,:,,:KPSFLICMOSSF236EORTC2C30WHO2100/BREFFACT,,,[5],,,,QLQ252018591,019242,6019404,0180,01334(P0101),,,Pearson01574(P0101),,;,,KMO01721,;Bartlettps,QLQ25217,6,,6,,0187,QLQ25294%,(P0105),QLQ252,93166%14130,12,83220056103ChineseClinicalOncology,Jun.2005,Vol.10,No.3,QLQ252,,:[1].[M].:,2002.137.[2].[M].:,2002.406-486.[3].[J].,2000,7(6):479.[4].[J].,2001,10(3):77.[5]WardeP.APhaseplacebo2controlledtrialoforalpilocarpineinpatientsundergoingradiotherapyforhead2and2neckcancer[J].IntJRadiatOncolBiolPhys,2002,54(1):9.:2004-10-01;:2004-12-04T1071000252,,,;T;:R737133:D:1009-0460(2005)03-0239-011,60,12002121,:,,,,,,013cm013cm,(+),,50,,,,,,;B:,,,,:,,,20031,,,,2,,:,T,20031161(PC:015g,,016g,,1,31),20033CHOP6,,2003720031120,,X,MRT4,T6,,,10mg10mg,3,CHOP,2,,200434,2,,,[1],,,,[2],,,[3]:(1),:;(2),COPCHOP();(3):,,,13,,:[1],,,.[M].:,2001.1053-1057.[2],,,.T[J].,1998,19(1):78.[3],.[J].,2003,19(3):164.:2004-09-16;:2004-12-2793220056103ChineseClinicalOncology,Jun.2005,Vol.10,No.3